Johnson & Johnson secured FDA approval Wednesday for icotrokinra, a new oral treatment for psoriasis that will be marketed under the brand name Icotyde. The drug is approved for patients 12 years and older suffering from the autoimmune skin condition.
Psoriasis affects millions of Americans and represents a significant market opportunity for pharmaceutical companies. Oral treatments offer convenience advantages over injectable biologics that currently dominate the market, potentially expanding patient access and compliance.